• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SMARCA4/BRG1 在卵巢小细胞癌伴高钙血症型(SCCOHT)中的重新表达通过 AP-1 依赖性机制促进上皮样基因特征。

Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.

机构信息

Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, United States.

出版信息

Elife. 2020 Dec 23;9:e59073. doi: 10.7554/eLife.59073.

DOI:10.7554/eLife.59073
PMID:33355532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7813545/
Abstract

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer. SCCOHT tumors have inactivating mutations in (BRG1), one of the two mutually exclusive ATPases of the SWI/SNF chromatin remodeling complex. To address the role that BRG1 loss plays in SCCOHT tumorigenesis, we performed integrative multi-omic analyses in SCCOHT cell lines +/- BRG1 reexpression. BRG1 reexpression induced a gene and protein signature similar to an epithelial cell and gained chromatin accessibility sites correlated with other epithelial originating TCGA tumors. Gained chromatin accessibility and BRG1 recruited sites were strongly enriched for transcription-factor-binding motifs of AP-1 family members. Furthermore, AP-1 motifs were enriched at the promoters of highly upregulated epithelial genes. Using a dominant-negative AP-1 cell line, we found that both AP-1 DNA-binding activity and BRG1 reexpression are necessary for the gene and protein expression of epithelial genes. Our study demonstrates that BRG1 reexpression drives an epithelial-like gene and protein signature in SCCOHT cells that depends upon by AP-1 activity.

摘要

卵巢小细胞癌,高钙血症型(SCCOHT)是一种罕见且侵袭性的卵巢癌形式。SCCOHT 肿瘤中存在 BRG1(SWI/SNF 染色质重塑复合物的两个相互排斥的 ATPase 之一)的失活突变。为了研究 BRG1 缺失在 SCCOHT 肿瘤发生中的作用,我们在 +/- BRG1 重新表达的 SCCOHT 细胞系中进行了综合多组学分析。BRG1 的重新表达诱导了类似于上皮细胞的基因和蛋白质特征,并获得了与其他上皮起源的 TCGA 肿瘤相关的染色质可及性位点。获得的染色质可及性和 BRG1 募集位点强烈富集了 AP-1 家族成员的转录因子结合基序。此外,AP-1 基序在上调的上皮基因的启动子处富集。使用显性负 AP-1 细胞系,我们发现 AP-1 DNA 结合活性和 BRG1 的重新表达对于上皮基因的基因和蛋白质表达都是必需的。我们的研究表明,BRG1 的重新表达在 SCCOHT 细胞中驱动上皮样基因和蛋白质特征,这取决于 AP-1 活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/7c74a094a71c/elife-59073-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/1a675ac2b107/elife-59073-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/1896afb20e66/elife-59073-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/ff6230bc664d/elife-59073-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/27328ae8b68c/elife-59073-fig1-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/c066601b250f/elife-59073-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/560f1d48f296/elife-59073-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/651e67ce59ab/elife-59073-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/5958329e4531/elife-59073-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/719556ee8b4c/elife-59073-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/31bff38d831c/elife-59073-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/207e1aa77a50/elife-59073-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/4d5cc008f109/elife-59073-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/9d9fdb918f28/elife-59073-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/4d9af66b9780/elife-59073-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/5942ded2f967/elife-59073-fig6-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/7c74a094a71c/elife-59073-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/1a675ac2b107/elife-59073-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/1896afb20e66/elife-59073-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/ff6230bc664d/elife-59073-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/27328ae8b68c/elife-59073-fig1-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/c066601b250f/elife-59073-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/560f1d48f296/elife-59073-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/651e67ce59ab/elife-59073-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/5958329e4531/elife-59073-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/719556ee8b4c/elife-59073-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/31bff38d831c/elife-59073-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/207e1aa77a50/elife-59073-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/4d5cc008f109/elife-59073-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/9d9fdb918f28/elife-59073-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/4d9af66b9780/elife-59073-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/5942ded2f967/elife-59073-fig6-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3139/7813545/7c74a094a71c/elife-59073-fig7.jpg

相似文献

1
Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.SMARCA4/BRG1 在卵巢小细胞癌伴高钙血症型(SCCOHT)中的重新表达通过 AP-1 依赖性机制促进上皮样基因特征。
Elife. 2020 Dec 23;9:e59073. doi: 10.7554/eLife.59073.
2
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.SWI/SNF复合物ATP酶SMARCA4/BRG1和SMARCA2/BRM的双重缺失对高钙血症型卵巢小细胞癌具有高度敏感性和特异性。
J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.
3
Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.综合基因组分析揭示了高钙血症型卵巢小细胞癌中SMARCA4基因失活突变和低肿瘤突变负荷。
Gynecol Oncol. 2017 Dec;147(3):626-633. doi: 10.1016/j.ygyno.2017.09.031. Epub 2017 Nov 6.
4
Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).卵巢高钙血症型小细胞癌(SCCOHT)中的双等位基因体细胞SMARCA4突变。
Pediatr Blood Cancer. 2015 Apr;62(4):728-30. doi: 10.1002/pbc.25279. Epub 2014 Oct 12.
5
Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with Recent Developments on Pathogenesis.高钙血症型卵巢小细胞癌(卵巢恶性横纹肌样瘤):发病机制最新进展综述
Surg Pathol Clin. 2016 Jun;9(2):215-26. doi: 10.1016/j.path.2016.01.005. Epub 2016 Apr 12.
6
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.卵巢高钙血症型小细胞癌中SMARCA2和SMARCA4表达的同时缺失。
Mod Pathol. 2016 Jan;29(1):60-6. doi: 10.1038/modpathol.2015.129. Epub 2015 Nov 13.
7
Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report.卵巢小细胞癌,高钙血症型:一例罕见病例报告
J Pediatr Adolesc Gynecol. 2023 Apr;36(2):112-115. doi: 10.1016/j.jpag.2022.10.004. Epub 2022 Oct 12.
8
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond Mutations: A Comprehensive Genomic Analysis.卵巢小细胞癌伴嗜血钙(SCCOHT),突变之外:全面的基因组分析。
Cells. 2020 Jun 19;9(6):1496. doi: 10.3390/cells9061496.
9
[Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].[卵巢小细胞癌,高钙血症型:临床病理特征分析及SMARCA4蛋白表达缺失的诊断效用]
Zhonghua Bing Li Xue Za Zhi. 2015 Dec;44(12):859-63.
10
SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.SMARCA4失活突变会导致伴发科芬-西里斯综合征、小眼畸形和卵巢高钙血症型小细胞癌。
J Pathol. 2017 Sep;243(1):9-15. doi: 10.1002/path.4926. Epub 2017 Jul 25.

引用本文的文献

1
Altered cofactor recruitment and nucleosome dynamics underlie bisphenol A's impact on ERα-mediated transcriptional bursting.辅因子募集和核小体动力学的改变是双酚A对雌激素受体α介导的转录爆发产生影响的基础。
iScience. 2025 Jun 10;28(7):112864. doi: 10.1016/j.isci.2025.112864. eCollection 2025 Jul 18.
2
MYC Regulates a DNA Repair Gene Expression Program in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.MYC调控高钙血症型卵巢小细胞癌中的一个DNA修复基因表达程序。
Cancers (Basel). 2025 Jul 7;17(13):2255. doi: 10.3390/cancers17132255.
3
Pioneering new enhancers by GATA3: role of facilitating transcription factors and chromatin remodeling.

本文引用的文献

1
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.重新分配 COV434 和 TOV-112D 卵巢癌细胞系的组织学特征。
Gynecol Oncol. 2021 Feb;160(2):568-578. doi: 10.1016/j.ygyno.2020.12.004. Epub 2020 Dec 13.
2
Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.SWI/SNF 染色质重塑缺失改变非小细胞肺癌中的 NRF2 信号通路。
Mol Cancer Res. 2020 Dec;18(12):1777-1788. doi: 10.1158/1541-7786.MCR-20-0082. Epub 2020 Aug 27.
3
Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1.
GATA3开创新型增强子:促进转录因子和染色质重塑的作用
Nucleic Acids Res. 2025 Jun 6;53(11). doi: 10.1093/nar/gkaf473.
4
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.SMARCA4缺失导致高钙血症型卵巢小细胞癌中内含子保留和肿瘤相关抗原的产生。
Cancer Res. 2025 Jul 15;85(14):2626-2642. doi: 10.1158/0008-5472.CAN-24-0044.
5
SMARCA4 regulates the NK-mediated killing of senescent cells.SMARCA4调节自然杀伤细胞介导的衰老细胞杀伤作用。
Sci Adv. 2025 Jan 17;11(3):eadn2811. doi: 10.1126/sciadv.adn2811. Epub 2025 Jan 15.
6
Efficacy of glutathione inhibitor eprenetapopt against the vulnerability of glutathione metabolism in SMARCA4-, SMARCB1- and PBRM1-deficient cancer cells.谷胱甘肽抑制剂依普奈他泊对SMARCA4、SMARCB1和PBRM1缺陷癌细胞中谷胱甘肽代谢脆弱性的疗效。
Sci Rep. 2024 Dec 28;14(1):31321. doi: 10.1038/s41598-024-82753-5.
7
CFTR represses a PDX1 axis to govern pancreatic ductal cell fate.囊性纤维化跨膜传导调节因子(CFTR)抑制PDX1轴以调控胰腺导管细胞命运。
iScience. 2024 Nov 15;27(12):111393. doi: 10.1016/j.isci.2024.111393. eCollection 2024 Dec 20.
8
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.异常的SWI/SNF复合物成员在罕见卵巢恶性肿瘤中占主导地位——耐药亚型中的治疗脆弱性。
Cancers (Basel). 2024 Sep 3;16(17):3068. doi: 10.3390/cancers16173068.
9
The CUT&RUN suspect list of problematic regions of the genome.基因组中存在问题的区域的 CUT&RUN 嫌疑列表。
Genome Biol. 2023 Aug 10;24(1):185. doi: 10.1186/s13059-023-03027-3.
10
Single-Cell Evolutionary Analysis Reveals Drivers of Plasticity and Mediators of Chemoresistance in Small Cell Lung Cancer.单细胞进化分析揭示小细胞肺癌可塑性的驱动因素和化疗耐药的中介。
Mol Cancer Res. 2023 Sep 1;21(9):892-907. doi: 10.1158/1541-7786.MCR-22-0881.
调控非经典先驱转录因子 PU.1 启动和重分布能力的机制。
Nat Commun. 2020 Jan 21;11(1):402. doi: 10.1038/s41467-019-13960-2.
4
Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies.上皮角蛋白:生物学及作为液体活检诊断标志物的意义。
Mol Aspects Med. 2020 Apr;72:100817. doi: 10.1016/j.mam.2019.09.001. Epub 2019 Sep 25.
5
Heterozygous Mutations in SMARCA2 Reprogram the Enhancer Landscape by Global Retargeting of SMARCA4.SMARCA2中的杂合突变通过SMARCA4的全局重新定位来重新编程增强子景观。
Mol Cell. 2019 Sep 5;75(5):891-904.e7. doi: 10.1016/j.molcel.2019.06.024. Epub 2019 Jul 30.
6
Inhibition of MYC by the SMARCB1 tumor suppressor.SMARCB1 抑癌基因对 MYC 的抑制作用。
Nat Commun. 2019 May 1;10(1):2014. doi: 10.1038/s41467-019-10022-5.
7
The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.哺乳动物 SWI/SNF 家族复合物的 ATP 酶模块介导亚基复合物身份和与催化活性无关的基因组靶向。
Nat Genet. 2019 Apr;51(4):618-626. doi: 10.1038/s41588-019-0363-5. Epub 2019 Mar 11.
8
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.CDK4/6 抑制剂针对 SMARCA4 决定的 cyclin D1 缺陷,靶向治疗高钙血症型卵巢小细胞癌。
Nat Commun. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.
9
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.SMARCA4 缺失与 CDK4/6 抑制在非小细胞肺癌中具有合成致死性。
Nat Commun. 2019 Feb 4;10(1):557. doi: 10.1038/s41467-019-08380-1.
10
RawTools: Rapid and Dynamic Interrogation of Orbitrap Data Files for Mass Spectrometer System Management.RawTools:用于质谱仪系统管理的快速动态 Orbitrap 数据文件查询
J Proteome Res. 2019 Feb 1;18(2):700-708. doi: 10.1021/acs.jproteome.8b00721. Epub 2018 Dec 3.